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Background

The Hospital Authority Scenario

Progress in medicine and breakthroughs from
bio-medical research have resulted in a rapid
proliferation of healthcare technologies including drugs,
equipment and interventional procedures.1 They are
often numerous, costly and holding great promises, with
safety and efficacy yet to be fully established.
Healthcare providers are thus under constant pressure
to decide for timely introduction of appropriate and
worthy technologies for benefit of patients, despite all
the uncertainties involved.
Worldwide experience demonstrates that
regulatory controls over emerging drugs and equipment
are better established than for interventional procedures.
It is not uncommon for the latter to involve intricate
elements of innovation, new consumables, variations
in application, and a high demand on operator skill to
achieve the intended outcome. Such degrees of
complexity often make the situation difficult to manage.
As no interventional procedures are free from hazards,
the decision to introduce a new procedure with its
associated uncertainties is not a simply task. A number
of government agencies and professional bodies have
made attempts to devise assessment tools to manage
this challenge, 2 in an effort to safeguard patient's
wellbeing and uphold professional accountability.

In Hong Kong, the Hospital Authority (HA) has
long established mechanisms to evaluate new drugs and
equipment for safety and efficacy prior to their
introduction into the system. Similar mechanism,
however, is not available for interventional procedures.
Section 22(e) (revised in June 1996) of the Professional
Code of Conduct issued by the Hong Kong Medical
Council stipulates that "The medical practitioner should
consult and obtain approval from the relevant ethical
committee in regard to the use of such surgical
procedures, grafts, implants or medications". When the
HA requested hospitals (or hospital clusters) to set up
their own ethics committees in 1995, it was intended
that they would deal with the introduction of new
interventional procedures as well. Yet the prevailing
practice is that only proposals on clinical trials would
be considered in the hospital ethics committees. Out of
the 12 major acute public hospitals surveyed in April
2000, few had established mechanism to evaluate new
interventional procedures prior to their introduction, and
most did not have explicit or sufficient documentation
requirements for such reviews. Situation does not seem
to be more assuring in the private sector (personal
enquiry). Anecdotal reports that new procedure of
unproven efficacy had been performed on patients
highlight the need for an explicit mechanism in HA and
perhaps Hong Kong as a whole.
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Evolution of HAMSINP
In January 2000, the Coordinating Committee in
Surgery reported to the Medical Services Development
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Committee (MSDC) that a mechanism would be set up
to vet new surgical procedures prior to their introduction
into HA. Members of MSDC received the proposal with
great enthusiasm. Thus, the Chairman, Dr the
Honourable CH Leong requested an explicit mechanism
to be established and implemented on the 1 January 2000
to cover all clinical specialties.
The 'HA mechanism for the safe introduction of
new procedures' (HAMSINP) was designed to close a
loophole in the existing system and to provide guidelines
and tools for HA staff to appraise new interventional
procedures and to document such activities. It was
planned with the following principles in mind:
1. It is considered unethical to plan an introduction of
new interventional procedure into the HA service
without going through proper peer review.
2. The mechanism must not stifle clinical innovation
but should, instead, facilitate timely assessment of
new procedures aiming at their safe and effective
introduction.
3. The mechanism would enhance accountability to
public, protecting interests of patients as well as the
clinicians and hospitals, through compliance with
an impartial process that is explicit, transparent and
benchmarked against international best practice.
4. The mechanism provides due recognition of staff
initiative, originality and fosters spirit of shared
learning.
Key results shall include:
1. Establishing Standard Operating Procedures (SOP)
for collecting, collating and analyzing evidence
concerning the safety and efficacy of submitted new
procedure, and making recommendations regarding
appropriate method of introduction into the HA
services.
2. Harmonizing vetting standards by providing a set
of unified procedures and appraisal tools.
3. Establishing documentation requirements that permit
retrospective evaluation of the conduct of the review
and the quality of the decision reached.
4. Enhancing cooperation and implementation planning
to minimise patient risks in going through many
learning curves of individual operators and centres.
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5. Setting up a central register to facilitate information
dissemination.
6. Developing a culture of accountability through
evidence-based decision making, independent peer
review and procedural transparency.

The Approach
We scanned websites for similar set ups in the
developed countries and conducted meetings to solicit
inputs from leading surgical specialists from both
Universities and HA hospitals. It was generally agreed
that the Australian Safety and Efficacy Register of New
Intervention Procedure - Surgical (ASERNIP-S)3 was
a model suitable for our adaptation. In April 2000, we
were fortunate to be offered an opportunity by Pamela
Youde Nethersole Eastern Hospital to test this model
on an application of intracoronary brachytherapy.4 We
subsequently developed a set of SOP and appraisal tools
using the evidence-based medicine approach.5,6 These
documents, grouped as HAMSINP during consultation,
constituted a common platform of discussion whereby
all interested staff could contribute their ideas. In
developing the SOP, we took care to align the
governance and management approval procedure with
the existing accountability structure in the HA hierarchy
(Figure 1).7
HAMSINP is application driven and its success
is thus contingent upon professional integrity and a
culture of accountability. Our professional obligation
dictates that all clinicians must assess safety and efficacy
issues before making changes or incorporates new
innovations in interventional procedure to their practice.
HAMSINP simply states these requirements and
emphasizes the need for systematic searching and
appraisal of evidence. The single unitary public hospital
system in Hong Kong which, covers over 90% of the
market, provides a unique opportunity to enable a
healthcare technology assessment tool with high
likelihood of success.
Noting that mutual understanding and trust are
prerequisite for the successful implementation of
HAMSINP. We would be holding more than 30 briefing
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INTRODUCTION OF NEW INTERVENTIONS
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Abbreviations:
CE: Chief Executive
CEU: Clinical Effectiveness Unit
COC: Coordinating Committee
COS: Chief of Service
DD(MSD): Deputy Director (Medical Services Development)
HA: Hospital Authority
HCE: Hospital Chief Executive
HGC: Hospital Governing Committee
MSDC: Medical Services Development Committee

Yes

Commission Review Group

Ratify by CE / designate

Inform applicant and HCE of recommendation.
File in the HAMSINP Register.

Figure 1. An overview of the HAMSINP mechanism.
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sessions and open forum for major specialty
Coordinating Committees, Hospital Governing
Committees and frontline practitioners to solicit their
comments.

the existing hospital ethics committee infrastructure
needs further development to match our community's
expectation.

Conclusion
What Have Been Confirmed
in the Consultation Process?
During consultation, both heat and light were
generated for HAMSINP. Concepts such as professional
autonomy, public accountability and practicability were
rigorously examined and debated upon among
enthusiastic colleagues. No one was left in doubt of the
principles and concepts of the proposed mechanism but
many had shown concerns over how much could be
achieved at the end. Many had pointed out difficulties
such as resources constraint and a prevailing culture of
competition among some hospitals that might obstruct
shared learning.
HAMSINP is application driven. It is not a
policing tool. The actual appraisal will be performed
by peers utilizing methods established in evidence-based
medical practice. This heavy involvement by clinicians
should strengthen the basis and further promotes
professional autonomy rather than limiting it as feared
by some colleagues. HAMSINP would not infringe upon
a clinician's sacrosanct privilege and duty in taking care
of his/her patients. In unforeseen circumstances where
a new procedure may be life saving, the accepted
practice to "act in good faith" would prevail over a
prescribed mechanism for normal use. Despite all
considerations and efforts to design a "perfect"
mechanism, the HAMSINP would need to evolve over
the years to fully achieve its intended objectives.
Innovations and hypothesis that needs to be
tested by clinical trials should be referred to the ethics
committee for consideration. The latter's scope is
much wider, covering issues such as bio-medical
ethics, scientific values and quality standards in the
designing, conducting, recording and reporting of
clinical trials.8 It is the authors considered view that

J HK Coll Cardiol, Vol 9

The HAMSINP helps to close a "loop hole" in
the existing system where some new procedures will
escape proper assessment by bypassing the ethics
committee. The limited experience we have gained
suggested reasonable confidence on its feasibility and
practicality. By making the best evidence and sound
recommendations clearly documented and readily
available, it will certainly facilitate better decisionmaking at all levels of healthcare in the Authority.
Readers interested in obtaining a copy of the
SOP, and or providing any comments, should contact
Dr SP Lim at splim@ha.org.hk.
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